Is there a line between ethics and market competition? Lights and shades of the withdrawal of collagenase treatment for Peyronie’s disease
- 22 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Impotence Research
- Vol. 34 (8), 733-734
- https://doi.org/10.1038/s41443-021-00469-w
Abstract
Peyronie’s disease treatments is changing again due the interruption of Xiapex® distrubution in Europe. There are many reasons that can be referred to this event. In this editorial we would like to shed light on the current cost items relating to treatment with collagenase clostridium histolyticum (CCH). The inaccessibility of the drug has seen both an increase in surgery for the treatments of both PD and Dupuytren’s disease and an interruption of therapies in patients who had not completed their therapeutic cycle. Considering the aforementioned concerns, we would like to invite researchers dealing with PD to conduct studies with the available CCH products in collaboration with the drug companies in order to give again an efficacious treatment for PD.Keywords
This publication has 6 references indexed in Scilit:
- European Association of Urology Guidelines on Sexual and Reproductive Health—2021 Update: Male Sexual DysfunctionEuropean Urology, 2021
- Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie’s Disease in an Era of Effective Clinical TreatmentThe Journal of Sexual Medicine, 2019
- Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian registerArchives of orthopaedic and trauma surgery, 2019
- Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the LiteratureEuropean Urology, 2018
- Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical studyBJU International, 2018
- Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 StudiesJournal of Urology, 2013